The FDA has taken significant steps to support use of real-world evidence (RWE) in drug and medical device decisions, but adoption within the life sciences industry remains slower than needed to meet growing industry demands. A lack of standardization for regulatory-grade real-world data (RWD) and the unique nature of each submission contribute to this cautious […]